(2R)-2-{[(tert-butoxy)carbonyl](methyl)amino}-3-(4-hydroxyphenyl)propanoic acid | 178208-61-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-{[(tert-butoxy)carbonyl](methyl)amino}-3-(4-hydroxyphenyl)propanoic acid
• 英文别名: N-(tert-Butoxycarbonyl)-N-methyl-D-tyrosine；(2R)-3-(4-hydroxyphenyl)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid
• CAS: 178208-61-2
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: APVBZIOLJVJCLT-GFCCVEGCSA-N

物化性质

• 沸点：
  458.4±40.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R)-2-{[(tert-butoxy)carbonyl](methyl)amino}-3-(4-hydroxyphenyl)propanoic acid 在 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 methyl (9S,12R)-12-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-4-nitro-11-oxo-2-oxa-10-azatricyclo[12.2.2.13,7]nonadeca-1(16),3,5,7(19),14,17-hexaene-9-carboxylate
  参考文献：
  名称：

  Alternative Synthesis of the Cycloisodityrosine Subunit of Deoxybouvardin, RA-VII, and Related Agents:  Reassignment of the Stereochemistry of Prior Intermediates

  摘要：

  DOI：

  10.1021/jo9604144
• 作为产物：
  描述：

  Boc-D-Tyr(Bzl)-OH 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 (2R)-2-{[(tert-butoxy)carbonyl](methyl)amino}-3-(4-hydroxyphenyl)propanoic acid
  参考文献：
  名称：

  Alternative Synthesis of the Cycloisodityrosine Subunit of Deoxybouvardin, RA-VII, and Related Agents:  Reassignment of the Stereochemistry of Prior Intermediates

  摘要：

  DOI：

  10.1021/jo9604144

文献信息

• Synthesis of (9<i>R</i>,12<i>S</i>)- and (9<i>S</i>,12<i>S</i>)-Cycloisodityrosine and Their <i>N</i>-Methyl Derivatives
  作者：Dale L. Boger、Jiacheng Zhou、Robert M. Borzilleri、Seiji Nukui、Steven L. Castle

  DOI：10.1021/jo961346o

  日期：1997.4.1

  Full details of the synthesis of (9R,12S)- and (9S,12S)-cycloisodityrosine and their N-methyl derivatives are detailed based on an intramolecular nucleophilic aromatic substitution reaction for formation of the key biaryl ether with 14-membered ring macrocyclization. Their comparison with prior samples and the documentation of a facile C9 epimerization within the natural 9S series are described.

  基于分子内亲核芳族取代反应以形成具有14元环大环化的关键联芳基醚，详细描述了（9R，12S）-和（9S，12S）-环异酪氨酸及其N-甲基衍生物的合成的详细信息。描述了它们与先前样品的比较以及天然9S系列中C9差向异构酶的简便记录。
• [EN] DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE DIAZEPINOINDOLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：PFIZER

  公开号：WO2004063198A1

  公开（公告）日：2004-07-29

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions, such as cancers.

  蛋白激酶，如CHK-1，抑制以下式的三环化合物（其中R2、R3和R4如规范中定义）的药物组合物，含有所述化合物或其盐的有效量，可用作单一药剂或与抗肿瘤药剂或具有抗肿瘤效果的治疗放射剂结合，用于治疗疾病或病况，如癌症。
• CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS
  申请人：ZHAO R. Yongxin

  公开号：US20170157262A1

  公开（公告）日：2017-06-08

  A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (I), wherein T, L, m, n, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , and R 13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

  一种具有公式（I）的细胞表面受体结合分子的强效细胞毒药物的共轭物，其中T、L、m、n、Y、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R12和R13在此定义，可用于靶向治疗癌症、自身免疫疾病和传染病。
• Conjugates of Cell Binding Molecules with Cytotoxic Agents
  申请人：Zhao R. Yongxin

  公开号：US20170296663A1

  公开（公告）日：2017-10-19

  A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

  一种有效的细胞毒性药物的共轭物，带有具有化学式（I）的细胞表面受体结合分子，其中T、L、m、n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和R13在此有定义，可用于靶向治疗癌症、自身免疫疾病和传染性疾病。
• Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
  申请人：Benedict Suzanne

  公开号：US20060004052A1

  公开（公告）日：2006-01-05

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R 2 , R 3 and R 4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

  蛋白激酶（例如CHK-1）抑制下列式子中三环化合物（其中R2，R3和R4如规范中定义）的药物组合物（或其盐）在单独使用或与具有抗肿瘤作用的抗肿瘤剂或治疗性放射线组合使用时，可用于治疗癌症等疾病或病况。